News from KI

Newsfeed delivered by KI.se

News from KI

Seminar September 19th: Quality Data Requires Healthy Mice

Monday August 21st, 2017 01:18:16 PM
Komparativ medicin

Animal health problems can delay studies and reduce the quality of data. This seminar outlines key decision points in planning and executing your research project, highlighting animal health resources and people who can help prevent unexpected outcomes. For example: 

  • How to read and understand animal health reports 
  • How to house mice and what different “barriers” mean 
  • What to do when animals get sick or die unexpectedly 
  • Case examples, highlighting problems and actions to solve them.

More about the program and registration

News category: 
News type: 
Organisational unit: 


Oral contraceptives linked to reduced risk of rheumatoid arthritis

Friday August 18th, 2017 08:12:16 AM
Kommunikationsavdelningen

Taking oral contraceptives is associated with a lowered risk of developing rheumatoid arthritis, finds a new observational study by researchers at Karolinska Institutet published in Annals of the Rheumatic Diseases. But no significant link was found for breastfeeding after accounting for various potentially influential factors.

The researchers analysed data from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) to find out if there is a link between the development of rheumatoid arthritis and use of oral contraceptives and/or breastfeeding among adult women who had had at least one child. The study included women aged 18 and above, living in defined areas of Sweden between 1996 and 2014. During this timeframe, 2809 women were diagnosed with rheumatoid arthritis. 5312 women randomly selected from the general population and matched for age acted as a control group.

Significantly reduced risk

The women were asked about their contraceptive and reproductive histories, their lifestyle, their education and whether they had breastfed their children. In addition, blood samples were taken to check for ACPA (anti-citrullinated protein) antibodies. Nine out of 10 people who test positive for ACPA antibodies will have rheumatoid arthritis, and the presence of these antibodies may indicate more serious disease.

The risk of developing ACPA-positive rheumatoid arthritis was 15 per cent lower in current users of oral contraceptives and 13 per cent lower in past users compared with women who had never used an oral contraceptive. Using the Pill for more than seven years was associated with a 19 per cent lower risk of developing both ACPA-positive and ACPA-negative rheumatoid arthritis. However, no firm conclusions can be drawn about cause and effect in an observational study, and the researchers lacked information about the dose or type of oral contraceptive.

Breastfeeding did not have the same effect

Although a lower risk was also found among women who had breastfed at least one child, this was not significant after having accounted for potentially influential factors.

The study was carried out by Cecilia Orellana at the Department of Clinical Neuroscience and Camilla Bengtsson at the Institute of Environmental Medicine, Karolinska Institutet, among others. The research was supported by grants from the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, King Gustav V’s 80-year foundation, Vinnova, the Swedish Foundation for Strategic Research, the Swedish Rheumatic Foundation, the Stockholm County Council, the Insurance Company AFA, the Innovative Medicines Initiative-supported BTCure project, and the National Institutes of Health.

This news article is based on a press release from Annals of the Rheumatic Diseases.

Publication

Cecilia Orellana, Saedis Saevarsdottir, Lars Klareskog, Elizabeth W. Karlson, Lars Alfredsson and Camilla Bengtsson. “Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study”. Annals of the Rheumatic Diseases, online 17 August 2017. doi 10.1136/annrheumdis-2017-211620

News category: 
News type: 


Nagihan Bostanci appointed as vice president for the Periodontal Research Group of IADR

Tuesday August 15th, 2017 01:21:55 PM
Cecilia Aflodal

Nagihan Bostanci has been appointed as the vice-president of the Periodontal Research Group of the International Association for Dental Research (IADR). She will serve as president-elect during the period 2018-2019 and will become the president for the period 2019-2020. The Periodontal Research Group enlists more than 1 100 members, and is one of the largest scientific groups of the IADR.

http://www.iadr.org/

News type: 


Current calls week 33, 2017

Tuesday August 15th, 2017 12:28:20 PM
Kia Olsson

Tips from KI Grants Office about current calls

Swedish and Nordic grants

Joint Japan-Sweden Research Collaboration – STINT

The aim of Joint Japan-Sweden Research Collaboration is to strengthen Swedish research and higher education by developing and establishing international partnerships. The programme supports projects of high scientific quality which are clearly contributing to the activities of participating institutions.

Closing date: 15 Sept 2017

Joint Japan-Sweden Research Collaboration – STINT 

Joint South Africa-Sweden Research Collaboration – STINT

The aim of the Joint South Africa-Sweden Research Collaboration programme is to strengthen Swedish research and higher education by developing and establishing international partnerships. The programme supports projects of high scientific quality which are clearly contributing to the activities of participating educational establishments. The programme is jointly funded by STINT, the Swedish Research Council (VR) and the Research Councils Formas and Forte on the Swedish side and the National Research Foundation on the South African side.

Closing date: 15 Sept 2017

Joint South Africa-Sweden Research Collaboration – STINT

Joint China-Sweden mobility – STINT

The aim of Joint China-Sweden Mobility is to strengthen Swedish research and higher education by developing and establishing international partnerships. The programme supports projects of high scientific quality which are clearly contributing to the activities of participating institutions.

Closing date: 26 Sept 2017

Joint China-Sweden mobility – STINT 

Postdoc stipendier - Birgit and Hellmuth Hertz' Foundation

Kungliga Fysiografiska Sällskapet i Lund inbjuder ansökningar om postdoktorsstipendium ur Birgit and Hellmuth Hertz’ Foundation. Detta ger yngre forskare möjlighet till förnyelse och forskning genom ett två eller tre-årigt projektanslag. Sökande ska ha avlagt doktorsexamen högst tio år före ansökningsdatum vid ett svenskt universitet eller teknisk högskola inom ämnesområdena naturvetenskap, medicin eller teknik. Anslag avser medel motsvarande lön samt drift om maximalt SEK 100,000 per år.

Closing date: 28 Sept 2017

Postdoc stipendier - Birgit and Hellmuth Hertz' Foundation 

PhD- and postdoc grants – The Nilsson-Ehle Endowments

The Royal Physiographic Society in Lund invites applications for the Nilsson-Ehle endowments. These support theoretical and applied research in genetics. Projects must have a direct bearing on the study of the structure, function and evolution of the genetic material or its practical use. Applicants must have at least two years of documented research experience in genetics. PhD students must include a letter of recommendation from the supervisor. Established researchers are not given preference over young researchers. Grants may cover costs for materials, laboratory animals and other running costs.

Closing date: 28 Sept 2017

PhD- and postdoc grants – The Nilsson-Ehle Endowments 

Geriatriska forskningsmedel – Stiftelsen för Gamla Tjänarinnor

Stiftelsen för Gamla Tjänarinnor utlyser forskningsmedel. Dessa främjar vetenskaplig forskning inom geriatriken.

Closing date: 30 Sept 2017

Geriatriska forskningsmedel – Stiftelsen för Gamla Tjänarinnor 

Forskningsanslag – Cancer- och Allergifonden

Cancer- och Allergifonden inbjuder ansökningar om forskningsanslag. Dessa stöder miljörelaterad cancer- och allergiforskning. Medel från fonden får inte användas till regelrätta djurförsök. Behöriga att söka är forskare anställda eller anknutna till svenska universitet eller högskolor. Anslag är värda upp till SEK 500,000 och omfattar ett år.

Closing date: 30 Sept 2017

Forskningsanslag – Cancer- och Allergifonden 

Symposieanslag

Marcus Wallenbergs Stiftelse för Internationellt Vetenskapligt Samarbete inbjuder bidrag för symposier. Dessa stöder anordning av internationella vetenskapliga symposier, forskar-utbildningsseminarier eller sommarskolor i Sverige. Ansökningar måste uppfylla följande kriterier: ha en tydlig akademisk förankring och håller hög vetenskaplig kvalitet; ha ett tydligt inslag av internationella föreläsare; äga rum i Sverige. Behöriga att söka är kvalificerade svenska forskare och institutioner. Ansökningar bör avse aktuella forskningsområden där svenska forskare är framstående.

Closing date: 1 Oct 2017

Marcus Wallenbergs Stiftelse för Internationellt Vetenskapligt Samarbete  

Patientnära forskning – Stiftelsen för Njursjuka

Dessa stöder forskning rörande patienter med kroniskt avancerad njursvikt eller som är njurtransplanterade. Den totala budgeten för år 2016 var SEK 400,000. Årets budget är ännu inte bestämd.

Closing date: 2 Oct 2017

Patientnära forskning – Stiftelsen för Njursjuka 

Postdoktorsstipendier för utbildning i Sverige – Wenner-Gren Foundations

Wenner-Gren Stiftelserna utlyser postdoktorsstipendier för utbildning i Sverige. Detta syftar till att möjliggöra för utländska disputerade forskare att verka vid en svensk vetenskaplig institution. Behöriga att söka är svenska forskare som är värd för en utländsk disputerad forskare. Den besökande postdoktorn skall ha avlagt doktorsexamen senare än fem år före ansökningstillfället och får inte ha vistats i Sverige mer än nio månader före ansökningstillfället. Ansökningar från unga forskare kommer att särskilt beaktas.

Closing date: 2 Oct 2017

Postdoktorsstipendier för utbildning i Sverige – Wenner-Gren Foundations 

European grants

Innovative Medicines Initiative - IMI2 Calls 11 and 12

On July 19th, the Innovative Medicines Initiative (IMI) launched the 11th and 12th Calls for Proposals under the IMI2 programme.

Call 11 supports the exploitation of results from specific, completed, IMI projects.

Call 12 is a two-stage call for collaborative research proposals on the following topics, with total budget from IMI of EUR 64 077 000:

Topic 1: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)

Topic 2: FAIRification of IMI and EFPIA data

Topic 3: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)

Topic 4: European Health Data Network (EHDN)

Topic 5: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations

Topic 6: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

Topic 7: European Screening Centre: unique library for attractive biology (ESCulab)

Closing date: 24 Oct 2017

Innovative Medicines Initiative - IMI2 Calls 11 and 12 

Special call for proposals 2017: ‘Myelin: from lesion to reparation’ - ARSEP Foundation

The ARSEP Foundation invites proposals for its special call for proposals. This supports scientific projects that focus on myelin – from lesion to reparation. Proposals should include at least two research laboratories, including one in France. Between two and three projects will receive €300,000 each. Funding for laboratory expenses, equipment and fellowships can be requested.

Closing date: 27 Sept 2017

Special call for proposals 2017: ‘Myelin: from lesion to reparation’ - ARSEP Foundation

Research grants - European Society of Clinical Microbiology and Infectious Diseases

ESCMID research grants enable young investigators to conduct research in the fields of clinical microbiology and infectious diseases, specifically bacterial infections and diseases including antibacterial susceptibility and resistance, diagnostics, pathogenesis, antibacterial stewardship, vaccines.

Applicants must be principal investigators of the proposed research and be ESCMID members, and must have been born on or after 1 January 1978. Grants are worth up to €20,000 each over a typical period of 12 months. Two grants of €50,000 are available for exceptional projects.

Closing date: 11 Oct 2017

Research grants - European Society of Clinical Microbiology and Infectious Diseases

Excellence award for sex and gender aspects in health research -- Berlin Institute of Health, DE

This award aims to bring more visibility to sex and gender issues in translational research. It recognizes research excellence among renowned scientists working in the field of basic and/or clinical biomedical research with a focus on sex and gender aspects. Applicants must be renowned scientists in the field of basic or clinical biomedical research; have made significant contributions to translational research with high relevance to the mission and strategy of Berlin Institute of Health (BIH); and have a focus on sex and gender aspects in their research.

The winner of the award will receive 20.000€ for use on future research activities with a focus on sex and/or gender aspects. Furthermore, BIH may nominate laureates as an Einstein BIH Visiting Fellow or BIH Visiting Professor to the Charité Foundation, if applicable.

Closing date: Applications are due on Oct 15, 2017

Excellence award for sex and gender aspects in health research -- Berlin Institute of Health, DE

US and international grants

Federal Funding agencies

Dissemination and implementation research in health (R01, R03, R21) - NIH

A total of 18 participating institutes and offices of the National Institutes of Health invite applications for this funding opportunity, which supports proposals that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices, such as behavioural interventions, prevention, early detection, diagnostic, treatment and disease management interventions, quality improvement programmes, into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Closing dates: Letters of intent due 30 days prior to the application due date; R01 applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2019 . R03 and R21 applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2019.

Funding Opportunity Announcement (FOA) Number: PAR-16-238 (R01)PAR-16-237 (R03)PAR-16-236 (R21)

EXTENDED DEADLINE: Exploratory clinical trials of mind and body interventions for NCCAM high priority research topics (R34)—NIH: National Center for Complementary and Alternative Medicine (NCCAM)

This funding opportunity supports early-phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM (also known as NCCIH) as high-priority research topics. It is intended to support exploratory clinical trials that will provide data critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial.

Priority areas include:

• the mind and body or integrated approach, including spinal manipulation, mobilisation, massage, tai chi, qi gong, yoga, acupuncture, hypnosis, guided imagery, light therapy, breathing activity, progressive relaxation, meditation, biofeedback, or mindfulness techniques;

• symptom management for chronic pain syndromes, reduction of prescription drug use or abuse in patients with chronic pain, medication adherence, post-traumatic stress, traumatic brain injury, sleep disorders or disturbances, anxiety, depression, promotion of psychological resilience, weight loss and weight loss maintenance, smoking cessation and promotion of healthy eating and physical activity.

Closing date: Oct 18, 2017, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA) Number: PAR-14-182

Strengthening implementation and use of effective health information systems through improved governance, design, planning and technical implementation under the President’s emergency plan for AIDS relief (PEPFAR) -- Centers for Disease Control and Prevention (CDC), US

This aims to:

• support the design, development, implementation, and evaluation of interoperable health information systems;

• improve policy, governance, and infrastructure needed to implement HIS;

• protect, secure, standardise, exchange and share data to improve health and increase sustainability and country ownership;

• sustain informatics workforce and capacity development.

Up to two awards worth up to USD 7.5 million each are available.

Closing date:  Estimated application due date: 11.59pm ET, 29 Sept 2017.

Funding Opportunity Number: CDC-RFA-GH18-1840

Healthy habits: timing for developing sustainable healthy behaviors in children and adolescents (R01, R21) -- NIH: National Institute of Nursing Research, US and other funders

This funding opportunity encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behavior in children and youth up to the age of 21. Applications to promote positive health behavior should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Applications from multidisciplinary teams are strongly encouraged. The maximum project period is five years.

Closing dates: Applications due by 5pm local time of the applicant organisation on 5 Oct 2017 (R01) and 16 Oct, 2017 (R21)

Funding Opportunity Announcement (FOA) Number: PA-14-177 (R01)PA-14-176 (R21)

Spatial uncertainty: data, modeling and communication (R01, R03, R21) -- NIH: National Cancer Institute, US and National Institute of Environmental Health Sciences

This funding opportunity supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

Closing dates: R01 applications due by 5pm local time of applicant organisation on 5 Oct, 2017. R03 and R21 applications due by 5pm local time of applicant organisation on 16 Oct, 2017.

Funding Opportunity Announcement (FOA) Number: PA-15-010 (R01), PA-15-011 (R03)PA-15-009 (R21)

Physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R01, R21) - NIH: National Cancer Institute, US and other funders

This announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control, on biomarkers of cancer prognosis among cancer survivors. Research topics of interest include:

•clinical studies to determine the optimal type and intensity of intervention for different subgroups of cancer survivors;

•studies with animal model components.

Closing dates: R01 applications due by 5pm local time of the applicant organisation every 5 Feb, 5 June and 5 Oct until 8 Sept 2018. R21 applications due by 5pm local time of applicant organisation every 16 Feb, 16 June and 16 Oct until 8 Sept 2018.

Funding Opportunity Announcement (FOA) Number: PAR-16-122 (R01)PAR-16-123 (R21)

Advancing understanding, prevention and management of infections transmitted from women to their infants (R01, R21) - NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development, US and other funders

This announcement supports research that will increase scientific understanding of and treatments for high-priority perinatal infections. The aim is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labour and delivery and breast-feeding.

Closing dates: R01 applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2019. R21 applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2019.

Funding Opportunity Announcement (FOA) Number: PA-16-032 (R01)PA-16-031 (R21)

Epilepsy research programme – US Department of Defense, US

Epilepsy risk factors award. This supports proposals to conduct preliminary studies to support prospective, longitudinal epidemiological research relevant to the characterization of post-traumatic epilepsy (PTE). Study design should indicate how the research strategy can generate preliminary data capable of supporting larger, more complex studies.  The proposed study design may be either prospective or retrospective.  Applications should describe how the association of traumatic brain injury (TBI) and subsequent PTE will be characterized. Applications should address at least one of the following Focus Areas:
 *   Epidemiology
 *   Markers and Mechanisms

Closing dates: Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), Sept 6, 2017. Application Submission Deadline: 11:59 p.m. ET, Sept 20, 2017

Funding Opportunity Announcement (FOA) Number: W81XWH-17-ERP-ERFA

Idea development award. This supports research to understand the magnitude and underlying mechanisms of post-traumatic epilepsy (PTE). Two levels of funding are offered under this call:

Funding Level I is intended to support high-risk or high-gain research. The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). The following Focus areas are open to Level I:
*   Epidemiology
 *   Markers and Mechanisms
 *   Models of PTE
 *   Psychogenic Non-Epileptic Seizures
Funding Level II is intended to support a more mature, hypothesis-driven research project. The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Closing dates: Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), Sept 6, 2017. Application Submission Deadline: 11:59 p.m. ET, Sept 20, 2017

Funding Opportunity Announcement (FOA) Number: W81XWH-17-ERP-IDA

Peer reviewed Alzheimer's research programme – US Department of Defense, US

Convergence science research award. This supports efforts to generate research resources and tools, or novel research efforts for professionals and practitioners in health sciences in the areas of traumatic brain injury (TBI) and its consequences on Alzheimer’s disease (AD) and related dementias (ADRD).

Funding Opportunity Announcement (FOA) Number: W81XWH-17-PRARP-CSRA

Quality of life research award. The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI,  AD, and ADRD and (2) reduce the burden of care on the caregivers for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent.  Both are equally important.

Funding Opportunity Announcement (FOA) Number:  W81XWH-17-PRARP-QUAL

Research Partnership Award. The intent is to create an avenue for collaborative research partnerships between investigators to address a research problem or question in a manner that would be unachievable through separate efforts. Applications must include clearly stated plans for interactions between the partners.  The plans must include communication, coordination or research progress and results, and data sharing between all investigators and organizations participating in the project.

Funding Opportunity Announcement (FOA) Number:  W81XWH-17-PRARP-RPA

New Investigator Award. The intent is to support early-career investigators interested in novel research efforts or new technologies addressing TBI and AD/ADRD. The PI must be an independent, early-career investigator within 4 years of his/her first independent faculty position (or equivalent).

Funding Opportunity Announcement (FOA) Number:  W81XWH-17-PRARP-NIRA

Closing dates: Pre-applications due by 5pm ET, 6 Sept; full applications due by 11.59pm ET, 20 Sept 2017.

Foundations

Specialized center of research program - Leukemia & Lymphoma Society, US

LLS’s Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Each SCOR is comprised of a minimum of three scientific Projects and a minimum of two scientific Cores that will cooperate under the leadership of a SCOR Director. There must be objective evidence of interdisciplinary research among the Projects and Cores. The maximal annual total cost is $1,000,000 for each year of the five year grant.

Closing dates: Letters of Intent due Sept 22, 2017 by 3:00 PM ET; Full Applications (by invitation only) due March 3, 2018 by 3:00 PM ET.

Specialized center of research program - Leukemia & Lymphoma Society, US 

Eugene Washington engagement awards - Patient-Centered Outcomes Research Institute, US

PCORI invites letters of intent for the Eugene Washington engagement awards. These support projects that encourage active integration of patients, caregivers, clinicians, and other healthcare stakeholders as integral members of the patient-centred outcomes and clinical effectiveness research enterprise.
 
Foreign organisations and non-domestic components of US applicant organisations may apply as long as there is demonstrable benefit to the US healthcare system and patient-centered research, and US efforts in the area of patient-centered research can be clearly shown. Awards are worth up to USD 250,000 for a maximum of two years.

Closing date: Letters of Intent (LOI) due Sept 29, 2017 by 5 p.m. ET.  Full proposals are due 40 days after review and approval of the LOI.  

Eugene Washington engagement awards - Patient-Centered Outcomes Research Institute, US 

Global oncology young investigator award - American Society of Clinical Oncology, US

This aims to develop the next generation of researchers to address global oncology needs by supporting early-career investigators to undertake oncology research. The goal is to apply the concepts of global health to cancer, and adopt an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world.  

Proposed research projects could include, but are not limited to:

  • Clinical and translational research
  • Innovative care delivery
  • Prevention and palliative care
  • Implementation research
  • Health Systems, Outcomes and Economics research related to cancer control and care

Applicants must apply within the last year of training or during the first two years of faculty or staff appointment or employment. They are not required to have oncology-specific training but should demonstrate an interest in oncology or related branch of science and be working in an oncology setting. 

Closing date: Applications due Sept 21, 2017

Global oncology young investigator award -- American Society of Clinical Oncology, US 

News type: 
Organisational unit: 


Professors Anna Martling and Ulf Hedin, both at MMK, are new members of the Board of Directors at CIMED

Tuesday August 15th, 2017 11:28:41 AM
Lilian Pagrot

CIMED, the Center for Innovative Medicine, is changing its focus and have a new board starting from 1 July 2017. In addition to the new board with a greater clinical competence, CIMED is to focus more on supporting clinical research than previously. Research on chronic diseases and diseases with a heavy disease burden will also have a high priority.

CIMED, whose objective is to find new treatments for endemic diseases, was inaugurated in 2015 and is funded primarily by SLL, but is a part of KI’s organization. SLL has now reviewed the support it provides to CIMED, which amounts to SEK 81 million annually. 

CIMED’s new board

Peter Lönnroth, professor, chair
Lars I Eriksson, professor, SLL
Anna Martling, professor, SLL
Annika Tibell, professor, SLL
Karin Dahlman-Wright, professor, KI
Ulf Hedin, professor, KI
Peter Stenvinkel, professor, KI

Read more about CIMED at: cimed.ki.se

News type: 


Maintenance work Ping Pong 18 August 2017 between 21.00 and 23.59

Tuesday August 15th, 2017 06:13:16 AM
KI IT-support

Hello,

On Friday August 18 between 21.00 and 23.59 hours there will be a service window to perform maintenance tasks on Ping Pong system of KI.

Ping Pong will be offline for a few minutes during the time period. We will inform any active users with a message in the application ahead of the interruption, but we would still advise you to inform any end users to avoid using the system during this time.

If you have any questions or doubts, please contact us at iktpedagogerna@ki.se.

Kind regards,

Team Ping Pong

News type: 


Killing bacteria by hacking plastics with silver and electricity

Monday August 14th, 2017 08:48:39 AM
Kommunikationsavdelningen

Researchers at the Swedish Medical Nanoscience Center at Karolinska Institutet have developed an innovative way of hacking conducting plastics so as to prevent bacterial growth using silver nanoparticles and a small electrical current. The method, which could prove to be useful in preventing bacterial infections in hospitals, is presented in the scientific journal Advanced Healthcare Materials.

Hospital wards are full of plastic surfaces, plastic tubes and plastic devices, each one potentially harbouring dangerous microbes. Bacteria are capable of surviving for a long time on plastic surfaces, from which they can spread to patients and cause infections.

Effective combination of small attacks

While both large electrical currents and high silver concentrations are known to kill bacteria, they also pose a risk to humans, which is why their use in hospitals is limited. New research lead by Professor Agneta Richter-Dahlfors at Karolinska Institutet’s Department of Neuroscience shows that it is not necessary to use dangerous concentrations of silver or large currents in order to kill bacteria, if these are used in combination.

“By targeting the bacteria on several fronts at the same time, the effect of different small attacks becomes larger than when each factor is acting on its own”, explains Agneta Richter-Dahlfors.

The research team focussed on the notorious hospital pathogen Staphylococcus aureus. They found that applying tiny electrical currents to a conducting plastic surface had no effect on bacterial growth. On a similar surface exposing an attached layer of silver nanoparticles, bacterial growth was reduced. However, application of a tiny electrical current to the latter surface enhanced the effect of attached silver nanoparticles, and the bacteria were completely destroyed.

Electrical fields weaken bacterial cells

“It’s a phenomenon known as the bioelectric effect, whereby electrical fields weaken bacterial cells against external attacks”, says PhD student Salvador Gomez-Carretero at Karolinska Institutet's Department of Neuroscience. “We use electrical signals to increase the antimicrobial activity of the silver nanoparticles. This reduces the amount of silver needed, which is beneficial for both the patient and the environment.”

In the future, the researchers hope that this technology will help to keep surfaces in hospitals and other settings requiring high hygienic standards free from bacteria that can cause life-threatening infections.

“It has not yet been tested in the clinic, but we believe this technology could be a good approach to limiting the spread of infectious bacteria and the incidence of hospital-acquired infections” says Professor Richter-Dahlfors.

The study was financed by the Swedish Research Council, Vinnova, Carl Bennet AB and the Swedish Medical Nanoscience Center.

Publication

Salvador Gomez-Carretero, Rolf Nybom and Agneta Richter-Dahlfors. Electroenhanced Antimicrobial Coating Based on Conjugated Polymers with Covalently Coupled Silver Nanoparticles Prevents Staphylococcus aureus Biofilm Formation. Advanced Healthcare Materials, online 14 August 2017. doi: 10.1002/adhm.201700435.

Image: 
Forskare i Richter-Dahlfors forskargrupp diskuterar resultaten i sina experimentella studier. Foto: Laurent Mekul Group members discussing experimental results in the Richter-Dahlfors lab. Photo: Laurent Mekul 
News category: 
News type: 


Eva Županič receives award at the EAN congress 2017

Monday August 14th, 2017 08:03:29 AM
Selma Wolofsky

Eva Županič, researcher at the Department of Neurobiology, Care Sciences and Society (NVS), has been awarded the Investigator Award at the Congress of the European Academy of Neurology (EAN) 2017.

Eva Županič receives the award for her research and presentation on the subject “Outcomes of thrombolysis treatment in patients with dementia and acute ischemic stroke – A longitudinal cohort study from SveDem and Riksstroke, Swedish Dementia and Stroke Registries”.

“I’m happy and thrilled our project received the Investigator award, it further underpins the importance and possibilities in epidemiological research”, she says. 

In the project, Eva Županič and her colleagues conducted a large nationwide study combining two national Swedish registers, SveDem (the Swedish dementia registry), and Riksstroke (the Swedish Stroke registry). 

They observed patients with dementia and acute ischemic stroke were less likely to receive a clot dissolving treatment with intravenous thrombolysis. They found no differences in intracerebral bleeding or death between dementia and non-dementia patients, however dementia patients had worse accommodation and functional outcomes at three months. 

Eva Županič is a PhD student at the Department of Neurology, University Medical Centre, Ljubljana, Slovenia, that does part of her doctoral studies at the NVS department. 

20 researchers have received the award for 2017, and in total 1 500 researchers submitted their work for evaluation.  The EAN Investigator Award is selected by the EAN Scientific Panels together with the Scientific Committee, who are responsible for the evaluation process before, as well as during, the congress. The prize consists of an award certificate and free registration to the Lisbon Congress in 2018.

Image: 
Eva Županič. Foto: Selma Wolofsky Eva Županič. Photo: Selma Wolofsky 
News category: 
News type: 


Karolinska Institutet number one in Sweden in innovation ranking

Friday August 11th, 2017 09:38:04 AM
Kommunikationsavdelningen

Karolinska Institutet (KI) is ranked 38 of 200 in the science magazine Nature's innovation ranking, Nature Index 2017 Innovation, which measures how companies and organizations use the university's research results. KI is the highest ranking Swedish university and the only one to enter the top 50.

The Nature Index Innovation report is based on how often research from academia and other public research institutions is cited in patents owned by non-academic organizations, for example companies in the IT, pharmaceutical and biomedical industries.

 "While one should be cautious about drawing far-reaching conclusions from rankings, this is an important indication of how KI stands in relation to other universities and a confirmation that we conduct high-quality research that is relevant to society at large,” says Ole Petter Ottersen, Vice-Chancellor at KI who took office on August 1.

To enter Nature Index Innovation, a university must have many publications in high-ranking scientific journals, and research findings that are applicable and cited in patents.

"This ranking provides a very interesting way to determine how university research contributes to the development of products of benefit to our society. It measures how third parties use our research findings to develop quality products and services," says Richard Cowburn, responsible for business collaboration at Karolinska Institutet.

USA in the top

American universities fill 38 of the top 50 spots in the Nature Index 2017 rankings; among the top five are Scripps Research Institute, San Diego, followed by Rockefeller University, New York; Massachusetts Institute of Technology, Boston; University of Massachusetts Medical School, Worcester and The University of Texas Southwestern Medical Center, Dallas.

KI is one of six European universities in the top 50. Other Swedish universities appearing in the list are Uppsala University and Stockholm University.

Nature Index Innovation bases its ranking on Lens, which is an open web-based tool that measures research's impact on innovations.

News type: 


New insight into how immune cells are formed

Thursday August 10th, 2017 11:14:49 AM
Kommunikationsavdelningen

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialised immune cell, does not depend on a growth factor called stem cell factor. This has been demonstrated in a new collaborative study by researchers at Karolinska Institutet and Uppsala University, and published in the scientific journal Blood. The results could pave the way for new treatments for certain types of blood diseases.

Allergy and asthma affect a high percentage of the population. Mast cells are specialised immune cells that play an important role not only in these conditions but also in other diseases such as mastocytosis, a haematologic disease involving an increased number of mast cells. It has been commonly understood that the growth factor stem cell factor, which stimulates mast cell development, is essential for the formation of mast cells. Now researchers at Karolinska Institutet and Uppsala University have shown that this is not the case. The researchers analysed mast cells and their progenitors in blood from patients with chronic myeloid leukaemia, a disease of the blood.

“When the patients were treated with the drug imatinib (Glivec), which blocks the effect of stem cell factor, the number of mature mast cells dropped, while the number of progenitor cells did not change. We were thus able to conclude that mast cell progenitors did not require stem cell factor”, says Professor Gunnar Nilsson at the Department of Medicine, Solna, and the Centre of Excellence for Systemic Mastocytosis at Karolinska Institutet, and Visiting Professor at the Department of Medical Sciences, Uppsala University, who led the study.

Could lead to new treatments

By culturing the mast cell progenitor cells present in blood, which are relatively uncommon (about 10 cells per million white blood cells), the researchers found that mast cell progenitors could survive, divide and partially mature without stem cell factor. Instead, development can take place with the factors interleukin 3 and 6.

“The study increases our understanding of how mast cells are formed and could be important in the development of new therapies, for example for mastocytosis for which treatment with imatinib/Glivec is not effective. One hypothesis that we will now test is whether interleukin 3 can be a new target in the treatment of mast cell-driven diseases”, comments Joakim Dahlin, Researcher at the Department of Medicine, Solna, at Karolinska Institutet and first author of the study.

The research has been financed with support from the Swedish Research Council, the Swedish Cancer Society, Ollie and Elof Ericsson’s Foundation, Hans von Kantzow’s Foundation, Tore Nilson’s Foundation, the Cancer and Allergy Foundation, The Cancer Research Funds of Radiumhemmet and Karolinska Institutet.

Publication

Joakim S Dahlin, Maria Ekoff, Jennine Grootens, Liza Löf, Rose-Marie Amini, Hans Hagberg, Johanna S Ungerstedt, Ulla Olsson-Strömberg, Gunnar Nilsson. KIT signaling is dispensable for human mast cell progenitor development. Blood, online 8 August 2017. doi: 10.1182/blood-2017-03-773374.

News category: 
News type: 







Feed aggregation powered by Syndicate Press.
Processed request in 0.01101 seconds.

Read more posts…